PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026JHEP Reports2 citationsOpen Access

Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study

MSMichael SchwarzMHMarlene HintersteiningerCSCaroline Schwarz

Key Points

  • This research investigates the long-term efficacy of response-guided bulevirtide combined with pegylated interferon for hepatitis D treatment.
  • Cohort study conducted at 10 specialized clinics
  • Patients were assessed for treatment response at 6-month intervals
  • Bulevirtide was provided with a response-guided approach, with PEG-IFN added for some patients.
  • 32.8% of patients achieved HDV-RNA TND 2
  • 10 patients discontinued bulevirtide treatment, with 3 experiencing a relapse
  • 19 patients received additional PEG-IFN, resulting in further declines in HDV-RNA and HBsAg levels.

Abstract

Rationale: Bulevirtide (BLV) is the only approved hepatitis D treatment Methods: Cohort study conducted at 10 specialized clinics PEG-IFN was added in a response-guided approach Treatment response was assessed at 6-month intervals Response-guided bulevirtide PEG-IFN treatment: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study Results: 61 patients were included HDV-RNA TND 2 was achieved by 32.8% 10 stopped BLV 1 but 3 relapsed 19 received add-on PEG-IFN resulting in a further decline of HDV-RNA and HBsAg

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schwarz et al. (2026) studied this question.

synapsesocial.com/papers/69c8c195de0f0f753b39bdc1https://doi.org/10.1016/j.jhepr.2026.101835
Ask AI
Helpful
Bookmark
Share
View Full Paper